AVEO Oncology

📍 Boston, United States🗓 Founded 2001👥 176 employees💰 Last funded Feb 2018
Biotechnology Research🌐 aveooncology.com
Website LinkedIn
AVEO is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immuno-oncology combinations in RCC and other indications, and has other investigational programs in clinical development. AVEO is committed to creating an environment of diversity, equity and inclusion to diversify representation within the Company.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
2001
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in AVEO Oncology?
AVEO Oncology has 1 investors on record on gritt.io.
When did AVEO Oncology last raise funding?
The most recent investment in AVEO Oncology recorded on gritt.io was in February 2018.
When was AVEO Oncology founded?
AVEO Oncology was founded in 2001.
What industry is AVEO Oncology in?
AVEO Oncology operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is AVEO Oncology based?
AVEO Oncology is headquartered in Boston, United States.